Back to top
more

ADMA Biologics (ADMA)

(Delayed Data from NSDQ)

$18.54 USD

18.54
3,634,555

-0.42 (-2.22%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $16.40 -2.14 (-11.54%) 4:40 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (144 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Is First Trust Small Cap Growth AlphaDEX ETF (FYC) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FYC

Zacks Equity Research

Brokers Suggest Investing in Adma Biologics (ADMA): Read This Before Placing a Bet

by Zacks Equity Research

Based on the average brokerage recommendation (ABR), Adma Biologics (ADMA) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Zacks Equity Research

Should First Trust Small Cap Growth AlphaDEX ETF (FYC) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for FYC

Zacks Equity Research

ADMA Biologics Inc (ADMA) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Adma Biologics (ADMA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Should First Trust Small Cap Core AlphaDEX ETF (FYX) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for FYX

Zacks Equity Research

Are Medical Stocks Lagging Addex Therapeutics (ADXN) This Year?

by Zacks Equity Research

Here is how Addex Therapeutics Ltd. Sponsored ADR (ADXN) and Adma Biologics (ADMA) have performed compared to their sector so far this year.

Zacks Equity Research

Recent Price Trend in Adma Biologics (ADMA) is Your Friend, Here's Why

by Zacks Equity Research

Adma Biologics (ADMA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Zacks Equity Research

Adma Biologics (ADMA) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Adma Biologics (ADMA) delivered earnings and revenue surprises of 15.38% and 11.74%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Should ADMA Biologics Stock Be in Your Portfolio Pre-Q3 Earnings?

by Zacks Equity Research

ADMA is having a stupendous run in 2024 so far on strong performance of Asceniv and high growth prospects.

Zacks Equity Research

CRISPR Therapeutics AG (CRSP) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

CRISPR Therapeutics (CRSP) delivered earnings and revenue surprises of 24.06% and 90.54%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Adma Biologics (ADMA) Soars 18.8%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Adma Biologics (ADMA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Wall Street Bulls Look Optimistic About Adma Biologics (ADMA): Should You Buy?

by Zacks Equity Research

Based on the average brokerage recommendation (ABR), Adma Biologics (ADMA) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Zacks Equity Research

Adma Biologics (ADMA) Exceeds Market Returns: Some Facts to Consider

by Zacks Equity Research

Adma Biologics (ADMA) concluded the recent trading session at $16.71, signifying a +1.7% move from its prior day's close.

Zacks Equity Research

Zai Lab Limited (ZLAB) Moves 14.7% Higher: Will This Strength Last?

by Zacks Equity Research

Zai Lab Limited (ZLAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Is First Trust Small Cap Core AlphaDEX ETF (FYX) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FYX

Zacks Equity Research

Adma Biologics (ADMA) Falls More Steeply Than Broader Market: What Investors Need to Know

by Zacks Equity Research

Adma Biologics (ADMA) closed the most recent trading day at $15.62, moving -1.01% from the previous trading session.

Zacks Equity Research

Adma Biologics (ADMA) Ascends While Market Falls: Some Facts to Note

by Zacks Equity Research

In the latest trading session, Adma Biologics (ADMA) closed at $16.58, marking a +1.28% move from the previous day.

Ekta Bagri headshot

ADMA Biologics Stock Skyrockets 262.1% YTD: How to Play the Stock?

by Ekta Bagri

ADMA stock rallies 262.1% in the year-to-date period on strong performance and high growth prospects. It recently hit its 52-week high with more room for growth.

Zacks Equity Research

Is It Worth Investing in Adma Biologics (ADMA) Based on Wall Street's Bullish Views?

by Zacks Equity Research

According to the average brokerage recommendation (ABR), one should invest in Adma Biologics (ADMA). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Zacks Equity Research

Zacks.com featured highlights include Atour Lifestyle, Vertiv, Corcept Therapeutics, Qifu Technology and ADMA Biologics

by Zacks Equity Research

Atour Lifestyle, Vertiv, Corcept Therapeutics, Qifu Technology and ADMA Biologics are part of the Zacks Screen of the Week article.

Nalak Das headshot

5 Stocks With Recent Price Strength Amid October Volatility

by Nalak Das

Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are ATAT, VRT, CORT, QFIN, ADMA.

Zacks Equity Research

Adma Biologics (ADMA) Stock Dips While Market Gains: Key Facts

by Zacks Equity Research

The latest trading day saw Adma Biologics (ADMA) settling at $20.33, representing a -1.91% change from its previous close.

Zacks Equity Research

SAGE's Dalzanemdor Fails to Meet Goal in Alzheimer's Disease Study

by Zacks Equity Research

The phase II LIGHTWAVE study evaluating Sage Therapeutics' dalzanemdor for treating cognitive issues due to Alzheimer's disease fails to meet the primary goal.

Zacks Equity Research

AstraZeneca Inks Agreement to Boost Cardiovascular Pipeline

by Zacks Equity Research

AZN inks an agreement with CSPC Pharmaceutical to develop a novel lipid-lowering therapy targeting various cardiovascular diseases.

Zacks Equity Research

New Strong Buy Stocks for October 7th

by Zacks Equity Research

ADMA, VERX, TRGP, EBMT and TALO have been added to the Zacks Rank #1 (Strong Buy) List on October 7, 2024.